title: [New perspectives of treatment with fesoterodine fumarate in patients with overactive bladder].
abstract: OBJECTIVE
  Evaluate the effect of the treatment with fesoterodine fumarate in patients with overactive bladder, as an alternative in case of failure of the usual anticholinergic treatment, due to either lack of therapeutic efficacy or due to intolerance to side effects.
  
  
  METHODS
  A retrospective review of 158 patients with overactive bladder was carried out. The patients were divided into two groups; the first group; 56 patients where the anticholinergic treatment showed to be ineffective, and the second group; 102 patients who presented intolerance to anticholinergic side effects.
  
  
  RESULTS
  For the first group where fesoterodine fumarate was used to improve effectiveness of the anticholinergics, improvement in the components of urinary urgency (p=0.001), insufficient emptying (p=0.001), incontinence (p=0.009), and in the number of pads/day (p<0.001) was detected. As to the second group where fesoterodine fumarate was used as an alternative to anticholinergics to avoid side effects, a high reduction in the incidence of dry mouth (p<0.001) and constipation (p=0.015) was seen, as well as a significant clinical improvement.
  
  
  CONCLUSIONS
  Fesoterodine fumarate is an optimal treatment option when the clinical response to anticholinergics has not been satisfactory, either by the lack of therapeutic action or by intolerance to side effects, and especially when the treatment is expected to be long.
authors: Unidad de Urología Funcional, Unidad de Gestión Clínica de Urología, Hospital Universitario Puerta del Mar, Cádiz, España. rgbaquero@hotmail.com
authors: R
authors: R
authors: García-Baquero
authors: B
authors: B
authors: Madurga
authors: M V
authors: MV
authors: García
authors: M A
authors: MA
authors: Fernández
authors: J M
authors: JM
authors: Rosety
authors: J L
authors: JL
authors: Álvarez-Ossorio
mesh_terms: D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D012189:Retrospective Studies; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D001559:Benzhydryl Compounds; D018680:Cholinergic Antagonists; D018727:Muscarinic Antagonists; C526675:fesoterodine